Faster gene-to-GMP with integrated E. coli GMP manufacturing – saves up to 3 months
Webinar Recap: From gene-to-GMP: making better E. coli production decisions earlier Webinar Date: September 30, 2026 | Organised by: enGenes...
Read the articleA first patient, a quiet promise: manufacturing vididencel for Mendus’s CML immunotherapy trial
A look at how NorthX Biologics’ vididencel GMP manufacturing for Mendus’s AML and CML immunotherapy trials and the patients’ unmet...
Read the articleInclusion bodies in recombinant protein production: friends or foes?
A practical guide to E. coli inclusion bodies, protein refolding strategies, and their role in recombinant protein manufacturing. Author: Agnes...
Read the articleJoining forces to tackle cholera
The urgent need for better cholera vaccines By NorthX Biologics | July 2026 Summary This article explores how NorthX Biologics...
Read the articleCHO cell line development
How to choose and build a high-performing cell line A practical guide to host selection, the CHO lineage, gene-integration systems,...
Read the articleBiologics development is more than 90 minutes
What the World Cup can teach us ⚽ By NorthX Biologics | June 2026 As football fans around the world...
Read the articleFrom bench to batch: the manufacturing imperative in allogeneic cell therapy
Why track record and translational fluency matter more than capacity alone Author: Hady Shahin, PhD, Scientist, NorthX Biologics In 2014,...
Read the articleThe CDMO’s unspoken role in the ATMP journey
Author: Luisa Lundin, PhD, Alliance and Communications Manager, NorthX BiologicsPublished by BioPharm International May 2026 Translating advanced therapy medicinal products...
Read the articleOuter membrane vesicles: From debris to biotech breakthrough
For decades, tiny membrane bubbles shed by bacteria were little more than a footnote in microbiology. First observed as obscure...
Read the articleEV drug delivery: The hype, the hope, and the GMP reality
Extracellular vesicles (EVs) have emerged as one of the most exciting modalities in biotherapeutics over the past decade. These nanoscale,...
Read the articleThe living medicine revolution: why 2026 marks cell therapy’s manufacturing moment
The cell and gene therapy sector has spent the past decade proving the transformative potential of living medicines that can...
Read the article